One of our clients, Miracor Medical, has made the announcement of the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. The trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI).
Miracor Medical is a Belgian company, located in Awans, that specializes in the treatment of cardiac diseases. In 2020, we supported Miracor in the raising of their series E financing round, which supported the development of the PiCSO technology in further stages. Click here to read the full report on the series E raising.
Want to read the full press release on the approval? Click here.
